(Q51893327)

17 April 2018

title

Reliability of a composite measure of social inclusion for people with psychiatric disabilities (English)

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

24 July 2024

1 reference

Chris Lloyd

1

1 reference

17 April 2018

Geoff Waghorn

2

1 reference

17 April 2018

Maria Best

3

1 reference

17 April 2018

Stuart Gemmell

4

1 reference

17 April 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20887433

24 July 2024

publication date

1 March 2008

1 reference

17 April 2018

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1630.2007.00656.x

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1630.2007.00656.x

24 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Australian Occupational Therapy Journal

24 July 2024

published in

1 reference

17 April 2018

volume

55

1 reference

17 April 2018

issue

1

1 reference

17 April 2018

page(s)

47-56

1 reference

17 April 2018

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Activation of the human androgen receptor through a protein kinase A signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Interleukin-6 regulation of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen receptor signaling: mechanism of interleukin-6 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Evolution of the androgen receptor pathway during progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen deprivation increases p300 expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

p300 modulates nuclear morphology in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen receptor decoy molecules block the growth of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Hypoxia increases androgen receptor activity in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: short- and long-term exposure affect proliferation and neuroendocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen-repressed phenotype in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Survivin mediates resistance to antiandrogen therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.1.47

Predicting the vocational capacity of the chronically mentally ill. Research and policy implications.

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

24 July 2024

Cronbach's alpha

5

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Social support and recovery in people with serious mental illnesses.

24 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Recovery as a psychological construct.

24 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Employment, social inclusion and mental health

24 July 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Assessing levels of adaptive functioning: the Role Functioning Scale

24 July 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

The multidimensional scale of independent functioning: a new instrument for measuring functional disability in psychiatric populations.

24 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Stigma, social justice and the rights of the mentally ill: challenging the status quo.

24 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

What is a clubhouse? Report on the ICCD 1996 survey of USA clubhouses.

24 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

The community integration measure: development and preliminary validation

24 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

24 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Restorying psychiatric disability: learning from first person recovery narratives.

24 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

The post-acute functioning of the schizophrenic

24 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Recovery principles and evidence-based practice: essential ingredients of service improvement.

24 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

24 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Classifying Socially-Valued Role Functioning Among Community Residents with Psychiatric Disorders

24 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

The employment of people with mental illness

24 July 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

Mental health consumers' experience of stigma.

24 July 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1440-1630.2007.00656.X

24 July 2024

Identifiers

10.2217/14750708.5.1.47

1 reference

17 April 2018

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20887433

24 July 2024

1 reference

17 April 2018